Arcturus Therapeutics
ARCT
19 hedge funds and large institutions have $7.87M invested in Arcturus Therapeutics in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 13 closing their positions.
5.44% more ownership
Funds ownership: 3.91% → 9.35% (+5.4%)
3% more capital invested
Capital invested by funds: $7.63M → $7.87M (+$239K)
21% less funds holding
Funds holding: 24 → 19 (-5)
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
54% less call options, than puts
Call options by funds: $45K | Put options by funds: $98K
Top Buyers
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$690K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$172K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$118K |
| 4 |
JP Morgan Chase
New York
|
+$107K |
| 5 |
VF
Virtu Financial
New York
|
+$97.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Geode Capital Management
Boston,
Massachusetts
| – | -$11K | -1,576 | Closed |
|
|
BHB
27
Bank Hapoalim BM
Tel Aviv,
Israel
| – | -$11K | -1,571 | Closed |
|
|
PCM
28
Prelude Capital Management
New York
| – | -$8K | -1,171 | Closed |
|
29
Bank of America
Charlotte,
North Carolina
| – | -$513 | -57 | Closed |
|
|
CA
30
Calton & Associates
Tampa,
Florida
| – | +$252 | +28 | New |
|
31
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | +$899 | +100 | New |
|
ARCT Hedge Fund Activity: Q4 2017 in Review
19 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2017, worth a combined $7.87M — up 3.1% from $7.63M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ARCT and 9 opened new positions — a net loss of 4 holders — while 4 trimmed existing stakes and 3 added.
The largest buyer was ARK Investment Management, opening a new position worth an estimated $690K. The largest seller was Knoll Capital Management, exiting entirely with an estimated $812K sold.
- 19 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2017, down from 24 in Q3 2017.
- Funds reported $7.87M of Arcturus Therapeutics stock for Q4 2017, up 3.1% quarter-over-quarter.
- 9 funds opened new Arcturus Therapeutics positions in Q4 2017 and 13 closed out, a net change of -4 holders.
- The largest Arcturus Therapeutics buyer in Q4 2017 was ARK Investment Management, an estimated $690K added.
- The largest Arcturus Therapeutics seller in Q4 2017 was Knoll Capital Management, an estimated $812K sold.
Based on aggregated 13F filings for Q4 2017.